HLS Therapeutics Inc. provided consolidated earnings guidance for the fiscal year 2024. for the year, the company expects consolidated revenue of $63.5 million-66.5 million, or 1%-5% growth.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.77 CAD | +1.34% | +0.27% | -4.56% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-4.56% | 86.87M | |
+23.92% | 74.5B | |
-2.46% | 24.24B | |
+10.52% | 8.45B | |
+4.65% | 8.44B | |
-21.71% | 7.65B | |
+11.90% | 5.24B | |
+2.27% | 4.14B | |
-4.23% | 3.95B | |
+5.42% | 3.83B |
- Stock Market
- Equities
- HLS Stock
- News HLS Therapeutics Inc.
- HLS Therapeutics Inc. Provides Consolidated Earnings Guidance for the Fiscal Year 2024